Skip to main content
. Author manuscript; available in PMC: 2010 Aug 23.
Published in final edited form as: J Immunol. 2009 Oct 21;183(10):6313–6319. doi: 10.4049/jimmunol.0803422

Figure 5. UCP2 decreases mast cell histidine decarboxylase expression.

Figure 5

(A) Real-time quantitative PCR of histidine decarboxylase mRNA transcripts from wild-type and Ucp2−/− BMMCs normalized to 18s rRNA. *P < 0.05. Data are the mean ± SD of three experiments. (B) Immunoblot of lysate from wild-type and Ucp2−/− BMMCs with anti-HDC antibody. Immunoblot is representative of three independent experiments with similar results. (C) Superoxide production of wild-type and Ucp2−/− BMMCs measured by dihydroethidium using flow cytometry. Histogram is representative of three experiments with similar results. (D) Total histamine content of BMMCs after 5 day treatment with TBAP (20–40 μM). *P < 0.05. Data are the mean ± SD (n=3).

HHS Vulnerability Disclosure